ANI Pharmaceuticals/$ANIP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ANI Pharmaceuticals
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Ticker
$ANIP
Sector
Primary listing
Employees
970
Headquarters
Website
ANIP Metrics
BasicAdvanced
$1.5B
21.81
$3.32
0.46
-
Price and volume
Market cap
$1.5B
Beta
0.46
52-week high
$99.50
52-week low
$56.71
Average daily volume
371K
Financial strength
Current ratio
2.708
Quick ratio
2.07
Long term debt to equity
112.625
Total debt to equity
116.193
Dividend payout ratio (TTM)
1.48%
Interest coverage (TTM)
2.59%
Profitability
EBITDA (TTM)
174.747
Gross margin (TTM)
61.36%
Net profit margin (TTM)
8.87%
Operating margin (TTM)
9.43%
Effective tax rate (TTM)
18.22%
Revenue per employee (TTM)
$910,000
Management effectiveness
Return on assets (TTM)
3.82%
Return on equity (TTM)
16.16%
Valuation
Price to earnings (TTM)
21.806
Price to revenue (TTM)
1.646
Price to book
2.81
Price to tangible book (TTM)
-1,184.86
Price to free cash flow (TTM)
9.707
Free cash flow yield (TTM)
10.30%
Free cash flow per share (TTM)
7.468
Growth
Revenue change (TTM)
43.78%
Earnings per share change (TTM)
-418.75%
3-year revenue growth (CAGR)
40.81%
10-year revenue growth (CAGR)
27.75%
3-year earnings per share growth (CAGR)
2.91%
10-year earnings per share growth (CAGR)
9.65%
What the Analysts think about ANIP
Analyst ratings (Buy, Hold, Sell) for ANI Pharmaceuticals stock.
ANIP Financial Performance
Revenues and expenses
ANIP Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ANI Pharmaceuticals stock?
ANI Pharmaceuticals (ANIP) has a market cap of $1.5B as of March 14, 2026.
What is the P/E ratio for ANI Pharmaceuticals stock?
The price to earnings (P/E) ratio for ANI Pharmaceuticals (ANIP) stock is 21.81 as of March 14, 2026.
Does ANI Pharmaceuticals stock pay dividends?
No, ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next ANI Pharmaceuticals dividend payment date?
ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders.
What is the beta indicator for ANI Pharmaceuticals?
ANI Pharmaceuticals (ANIP) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.